30 studies found for:    "Wiskott-Aldrich syndrome"
Show Display Options
Rank Status Study
21 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
22 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine  phosphate 30 mg;   Drug: MESNA
23 Active, not recruiting Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
24 Completed Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
Conditions: Immunologic Deficiency Syndrome;   Agammaglobulinemia;   Severe Combined Immunodeficiency;   Wiskott-Aldrich Syndrome;   Common Variable Immunodeficiency
Interventions: Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;   Drug: Dextrose, 5% in Water
25 Completed Evaluation of Immunological Disorders of T Lymphocytes and Endocrinological Disorders as Pathogen Factors in Patients With Metaplasia of Urinary Bladder
Conditions: The Follow-up Duration Was 1-8 Years.;   The Main Reasons Behind Visiting the Hospital Were Recurrent Urinary Tract Infection,;   Urinary Urgencies, Pollakiuria, Difficulty in Initiating Micturition, Pain in Hypogastrium,;   Night Wetting and Day Wetting, Menstruation's Disorders, Urolithiasis, Defects of Urinary;   System and Hematuria.
Interventions: Drug: Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution;   Drug: cephalosporin with chemotherapeutics
26 Recruiting Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
27 Recruiting Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Condition: Non-Malignant
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
28 Completed Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Condition: Blood Coagulation Disorders
Intervention:
29 Enrolling by invitation Molecular and Clinical Studies of Primary Immunodeficiency Diseases
Condition: Immunologic Deficiency Syndrome
Intervention:
30 Completed Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects
Condition: Primary Immune Deficiency Disease
Intervention: Biological: Flebogamma 5% DIF

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-30) Next Page   
Indicates status has not been verified in more than two years